Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13967018 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL17664755 | 0.79 | PIK3CD (0.31) | — | |
| SCHEMBL13804488 | 0.77 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL148821 | 0.77 | CA2 (0.36) | — | |
| SCHEMBL2422937 | 0.77 | CA2 (0.36) | — | |
| SCHEMBL18177130 | 0.76 | — | — | |
| SCHEMBL18177132 | 0.76 | — | — | |
| SCHEMBL7756606 | 0.75 | CNR2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL837997 | 0.75 | CA2 (0.35) | — | |
| SCHEMBL17662565 | 0.74 | MMP8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122792-A1 | MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES | KINETA CHRONIC PAIN, LLC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122792-A1 | MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES | CHRNA9, CHRNA10, CHRNA7 | L3MBTL1 2804/4885 |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | L3MBTL1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.